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Abstract:
In North America a high proportion of pregnant women use herbal medications, including
North American ginseng. This medicinal plant contains a high amount of triterpene
saponins (ginsenosides) which are the main bioactive compounds. It is important to assess
ginseng’s impact on all reproductive functions to ensure the safety of pregnant women and
fetuses. In this study, we defined the concentration responsive effects of North American
alcoholic and aqueous ginseng extracts on preimplantation development in vitro and on
pregnancy and post-partum development in the mouse. Two-cell mouse embryos were
cultured with 5 different concentrations of whole ginseng root extracts, or ginsenosides
Rb1, Rg1 and Re alone, a combinatorial ginsenoside solution and a crude polysaccharide
fraction solution. Embryonic development and recovery from treatment was assessed. To
investigate in vivo effects of ginseng extracts, female mice were gavaged with
50mg/kg/day, 500mg/kg/day or 2000mg/kg/day of either extract (treatment) or water
(sham) for 2 weeks prior to mating and throughout gestation. Gestation period, litter size,
pup growth and pup sex ratio were evaluated. Oral ginseng consumption did not
significantly affect fertility or pregnancy in the mouse. High doses of ginseng
(2000mg/kg/day) decreased maternal weight gain. Direct treatment of preimplantation
embryos in vitro demonstrated that ALC and AQ extract treatment reduced development
in a concentration responsive manner, while only ALC extract effects were largely
reversible. Treatments with individual or combinatorial ginsenosides or polysaccharide
fraction solution alone did not impair preimplantation development, in vitro. In conclusion,
maternal oral consumption of ginseng has little negative impact on pregnancy in the mouse
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however direct exposure to ginseng extract during mouse preimplantation development in
vitro is detrimental.
Key Words: ginseng, ginsenosides, fertility, blastocyst, pregnancy, assisted reproductive
technologies
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Introduction:
Ginseng is one of the ten most commonly used herbal medicines in the United
States (Bent and Ko, 2004; Chu and Zhang, 2009). Ginseng extracts have reported benefits
to the cardiovascular, nervous and the reproductive systems (Attele et al., 1999). In the US,
9-45% of pregnant women use herbal supplements during pregnancy (Eisenberg et al.,
1998; Gibson et al., 2001; Tsui et al., 2001; Glover et al., 2003), with 2.4% ingesting
ginseng (Glover et al., 2003). Use of herbal products varies from 26-40% of European
women during pregnancy (Bishop et al., 2011; Nordeng et al., 2011). In China, up to 15%
of women consume ginseng during pregnancy, as it is believed to be “good for pregnancy
and the fetus” (Ong et al., 2005). Herbal remedies are often deemed harmless because they
are “natural”, but this does not in any way ensure that consumption of ginseng is safe for
preimplantation development or pregnancy (De Smet et al., 2004). Most herbal products
carry a warning label to not consume during pregnancy. This is related to the lack of
scientific information on safety during pregnancy. Approximately 40 ginsenoside
compounds have been identified from the ginseng root (Fuzzati, 2004). Ginsenosides
belong to a family of steroids called triterpene saponins (Attele et al., 1999) and are either
derivatives of the (20S)-protopanaxadiols (PD), (20S)-protopanaxatriols (PT, Tawab et al.,
2003), acotillol-type or oleanolic acid groups (Fuzzati, 2004). The other major component
found in water extract is polysaccharides, which are sugar polymers that have immunemodulatory activity.
To date, research investigating ginseng’s impact on reproductive function has
demonstrated lower morphological scores for in vitro treated rat and mouse postimplantation embryos than for control embryos (Chan et al., 2003, 2004; Liu et al., 2005,
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2006). Conversely, Lee et al. (2008) found treatment of early rat embryos with individual
ginsenosides resulted in either no significant change to the morphological scores or
improvements. In addition, very recent in vivo studies have shown that when up to 2000
mg/kg/day (≈200 times the recommended clinical dose) of Korean Red Ginseng extract
was administered to female mice, maternal weight, feeding, embryonic implantation and
fetal growth were not significantly affected (Shin et al., 2010).
It is important to establish whether consumption of ginseng extracts are safe during
pregnancy and what effects, if any, direct exposure to these extracts may have on
preimplantation development. North American ginseng (NAG) has a much higher
concentration of ginsenosides Rb1 and Re, and little Rf compared to Asian ginseng extract
(Kitts et al., 2000; Sievenpiper et al., 2004; Sun et al., 2011). Furthermore, the alcoholic
(ALC) extract derived from NAG possesses twice the total concentration of ginsenosides
as the Aqueous (AQ) extract, specifically 282.5 mg/g versus 138.7 mg/g (Azike et al.,
2011). In addition, the AQ extract is composed of 15% polysaccharides, whereas the ALC
extract has none. Finally, due to so much variability between the compounds found in
different ginseng products (Liberti and Der Marderosian, 1978), it is important to study the
effects of different ginseng species and extracts on reproduction, which is why the aqueous
and alcoholic extracts produced from NAG are the focus of this research.

Materials and Methods
Chemicals
KSOMaa (potassium simplex optimized medium with amino acids) was used for embryo
culture medium (EMD Millipore Corporation, Billerica, MA, USA). The Ontario Ginseng
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Growers Association provided four-year-old North American ginseng roots, which were
extracted to produce the AQ and ALC fractions (Azike et al., 2011).

The crude

polysaccharide preparation was obtained after precipitation from AQ extract in the
presence of 40% alcohol (Azike et al., 2011). Ginsenosides Rb1, Rg1 and Re were
purchased from Sigma (St. Louis, MO. USA).

Animals
All animal care and handling procedures were conducted as approved by the University of
Western Ontario, Animal Care and Veterinary Science (ACVS), standard operating
procedures that conform to guidelines produced by the Canadian Council for Animal Care
(CCAC). Six-eight week old female MF1 mice were purchased from Harlan Laboratories
(Indiana, USA) and CD1 mice were purchased from Charles River (Canada). Each female
was injected with 7.5 units of Pregnant mares serum gonadotrophin (Folligon, Intervet,
Whitby, ON), then 7.5 units of human chorionic gonadotrophin (Chorulon, Intervet) 48 h
later and placed with CD1 males for mating. Pregnancy was confirmed the following
morning by the presence of a vaginal plug which was considered gestational day one. On
gestational day two, the mice were euthanized employing CO2 asphyxiation, followed by
cervical dislocation. Oviducts were dissected and two-cell stage embryos were flushed with
M2 flushing medium (Sigma, St. Louis, MO, USA). For all in vitro treatment experiments,
20 embryos were cultured in 20 μl drops under oil at 37°C under a 5% O2, 5% CO2 and
90% N2 atmosphere for 48 h.

6

In vitro Experimental Sequence
Alcohol and Aqueous Ginseng Extracts
Two-cell embryos were washed three times in KSOMaa. Individual stock solutions (10,000
μg/ml) of the alcoholic and aqueous ginseng extracts were made in KSOMaa. These stock
solutions were diluted to prepare: 0 (control), 10, 50, 250 and 1000 μg/ml of each extract.

Individual Ginsenoside Rb1, Rg1 and, Re Treatments
Ginsenoside concentrations were calculated to equal the highest actual individual
concentrations in either of the AQ and ALC extracts. One mg of ginsenoside Rb1, Rg1 and
Re were individually mixed with 1 mL KSOMaa to prepare 1000 μg/ml stock solutions.
The stock solutions were then diluted for each individual ginsenoside as follows: Rb1
164.5, 41.1, 8.2, 1.6 and 0 μg/ml; Rg1 13.1, 2.6, 0.66, 0.15 and 0 μg/ml and Re 89.6, 22.4,
4.5, 0.9 and 0 μg/ml.

Ginsenoside Combinatorial Experiments
Two-cell embryos were washed three times in KSOMaa. Ginsenoside concentrations were
calculated to equal the actual individual concentrations of Rb1, Rg1 and Re found in the
ALC extract. Three individual stock solutions (1000 μg/ml) of purified ginsenoside Rb1,
Rg1 and Re were made. The stock solutions were diluted to equal the 257.1 μg/ml
concentration found in 1000 μg/ml of the alcoholic extract: which consisted of Rb1 (64%);
Rg1 (1%) and Re (35%). This stock was then diluted to provide the five treatment
concentrations of 257.1, 64.3, 12.9, 2.6 and 0 μg/ml.
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Polysaccharide Fraction
For all polysaccharide fraction (PSF) experiments, CD1 females were used. Fifteen
percent of the aqueous extract is composed of PSF, thus this percentage was used to
calculate the maximum concentration in 1000 μg/ml AQ extract. A stock solution of 10,000
μg/ml PSF was made and then this stock solution was adjusted to the following
concentrations: 150, 37.5, 7.5, 1.5 and 0 μg/ml.

Morphological Assessment
For all in vitro experiments, embryo development was assessed after 48 h of treatment.
After treatment and culture, the cell number of each embryo was determined and
categorized into 2, 4 or 8 cells, 8-cell compacted, morula or blastocyst groups.

Recovery from Treatment
After the morphological assessment following 48 h of treatment, embryos in all
experiments were washed three times in fresh ginseng or ginsenoside free KSOMaa and
returned to culture for another 72 h in order to determine if recovery from ginseng exposure
was possible. After 24 and 72 h, embryos were once again categorized into their specific
developmental stages.

In vivo experiments
Animals
In the first two experiments, female MF1 mice (six-eight weeks old) were gavaged for 14
days prior to mating and throughout gestation. For the third experiment, CD1 females were
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used, as MF1 mice were no longer commercially available. Three experiments were
conducted, females gavaged 50 mg/kg/day (MF1), females gavaged 500 mg/kg/day (MF1),
and females gavaged 2000 mg/kg/day (CD1) for 14 days prior to mating and throughout
gestation. The experiments consisted of three treatment groups: sham-gavaged water,
aqueous extract and alcoholic extract. When administering a dose of 500 or 2000
mg/kg/day, the solutions were prepared 10 or 40 times more concentrated than the 50
mg/kg/day concentration to keep volumes gavaged to a maximum of 0.3 ml total
volume/day. Females were gavaged (using standard operating procedures as outlined by
Western University’s ACVS) once per day for 14 days prior to natural mating and during
gestation. The volume gavaged was calculated according to individual mouse weights and
adjusted as the mouse gained weight during pregnancy. Females were naturally mated by
placing with CD1 males for up to five days. Following detection of a vaginal plug, females
were separated from males and placed into individual cages until they gave birth. N values
were 4-6 pregnant mice per treatment group per experiment.

Outcome Assessment
Once litters were born, day of birth, litter size, and gestation period were determined for
each group in each experiment. Pups were individually weighed every four days until
weaning on post-partum day 20. Offspring sex was determined at weaning.

Statistical Analysis
Statistical analyses were done with GraphPad Prism version 4.0c software or SigmaStat
3.5 (Jandel Scientific, San Jose, CA). Each culture experiment was repeated a minimum of
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three times using embryos collected from replicate groups of mice. Data are presented as
the mean ± standard deviation (SD). For in vivo experiments, litter size, gestation period
and proportion of male pups, statistical analyses were conducted with ANOVA. Where the
conditions of normality or equal variance were not met, the Kruskal-Wallis non-parametric
test on ranks was used. To correct for litter size, the mean pup or male/female pup weight
was used for each litter in the analysis. We report on the results of one-way ANOVA for
weights on the day of birth and at weaning. A two-way ANOVA analysis was used to
examine the effects of treatment and sex on pup weight at weaning (D20). For maternal
weights in the 2000 mg/kg/day experiment, during group housing in the feeding period
before pregnancy, one-way ANOVA was used to detect treatment differences. During
lactation, two-way ANOVA with repeated measures was used to evaluate maternal
weights, multiple comparisons performed when effects were significant, n values were 56. Data were subjected to a reciprocal transformation p < 0.05 was considered to be
statistically significant.

Results
Effect of Aqueous Ginseng Extract Treatment on Mouse Preimplantation
Development in vitro.
Aqueous ginseng extract treatment resulted in a concentration-dependent inhibition
of preimplantation development (Figure 1A). As the concentration of AQ extract increased,
the number of embryos developing to the morula and blastocyst stages was significantly
reduced (p<0.05). Development was increasingly blocked at the two-cell and four-cell
stages (Figure 1A). At 1000 μg/ml, only 1.5% of embryos developed to the morula stage,
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whereas 71.7% of control embryos progressed to the morula stage after 48 hours of culture.
Embryos treated with 10 μg/ml of the aqueous extract displayed the greatest recovery from
treatment as blastocyst formation increased to nearly 80% blastocysts after 72 h of recovery
time (Figure 1B). Exposure to all higher aqueous concentrations resulted in no
development to the blastocyst stage at 48h of culture (p<0.05) and very limited recovery
compared with the control (Figure 1B).

Effect of Alcoholic Ginseng Extract Treatment on Mouse Preimplantation
Development in vitro.
Treatment with the alcoholic extract resulted in similar outcomes as that of the
aqueous fraction, with concentrations of 50 and 250 μg/ml significantly (p<0.05)
increasing the numbers of embryos blocked in development at the two-cell stage (Figure
2A). Paradoxically, treatment with 1000 μg/ml did not result in developmental arrest
(Figure 2A). All doses however resulted in decreased blastocyst development at 48h of
culture (p<0.05). Embryos treated with 10, 50 and 1000 μg/ml of ALC extract recovered
from treatment by displaying no significant difference in blastocyst formation after 72 hour
recovery period (Figure 2B). Interestingly, the developmental blockade resulting from
treatment with 250 μg/ml ALC extract was only marginally reversed with 29.4% of treated
embryos developing to the blastocyst stage, as opposed to 97.1% for control after 72 h of
recovery time (Figure 2B).
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Effect of Individual and Combinatorial Ginsenosides Rb1, Rg1, Re and
Polysaccharide (PSF) Fraction Treatment on Mouse Preimplantation Development
in vitro.
Experimentation using the highest Rb1 concentration found in our extracts resulted
in a significant decrease (p<0.05) in development to the morula stage between the control
and 8.2 μg/ml of Rb1 (Figure 3A). However, following washing and recovery period, there
were no differences in blastocyst development at 24h and 72h (Figure 3B). Embryos
exposed to even the highest Rg1 concentrations found in our extracts progressed normally
to the blastocyst stage (Figures 4A, B). In experiments conducted with ginsenoside
concentrations of Re found in our preparations, no significant variations in embryo
development between the control and treatment groups were observed (data not shown).
Likewise experiments using combinatorial ginsenoside concentrations resulted in no
significant impairment in development to the blastocyst stage (data not shown). Finally we
treated two-cell stage embryos with polysaccharide fraction concentrations up to that found
in the AQ fraction and also did not observe any significant impairment of development to
the blastocyst stage (data not shown).

Effects of oral consumption of either Ginseng Extract on Pregnancy and Post-Partum
Development in the Mouse

Females Gavaged with 50 and 500 mg/kg/day Ginseng Extracts
Parturition was checked twice daily (day of copulation plug = D1), the gestation
period and litter size were determined (Table 1). No significant differences were observed
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between treatment groups for litter size or sex ratio in any of the gavage treatments (Table
1). Pup weights were determined by weighing 247 individual pups (50 mg/kg/day) and 212
pups (500 mg/kg/day). There were no sex-specific pup weight differences at weaning due
to treatment (data not shown).

Females Gavaged with 2000 mg/kg Ginseng Extracts
Weight of the females were not significantly different at the start of the treatment
(Figure 5A), but after one week the ginseng groups weighed less than the SHAM group
(p<0.05, Figure 5A). Ginseng treated females maintained this difference throughout the
feeding period. For individual pregnancy (Figure 5A) days, there were significant effects
due to treatment, all p < 0.05. By the last gestational day SHAM animals weighed 7-8g
more than the ginseng treated females (Figure 5B). For repeated lactation weights (Figure
5B), there were significant differences due to treatment (p<0.01) and days (p<0.01).
During lactation, The AQ extract group weighed less than the SHAM animals (Figure 5B).
The average number of pups per litter on the day of birth did not vary significantly between
treatment groups (Table 1). To evaluate pup growth and development, 173 pups were
individually weighed every four days to Day 20. Sex ratio of the pups did not differ among
groups (Table 1).

Discussion
There is a need to investigate the safety of North American ginseng consumption
on preimplantation development, pregnancy and post-partum development as assessed in
this study. We have discovered that AQ and ALC North American ginseng extract
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treatments caused a concentration dependent inhibition of development when applied
directly to preimplantation embryos in culture, with the AQ extract causing more
permanent effects. Exposure to individual ginsenosides, Rb1 and Rg1, did not produce
lasting effects in vitro. Importantly, however, pregnancy was unaffected with orally
administered NAG extracts up to 2000 mg/kg/day. This study indicates that direct exposure
to ginseng extracts is detrimental to the completion of preimplantation development.
The effect of ginseng and ginsenosides on postimplantation embryos has been
examined (Chan et al., 2003, 2004; Liu et al., 2005, 2006; Lee et al., 2008), however, few
studies have investigated the direct influence on preimplantation embryo development.
Our in vitro study shows differences between treatments with the two types of
extracts. Excluding embryos treated with the 250 μg/ml dose, all other groups treated with
the ALC extract recovered from treatment and progressed onto the blastocyst stage after
recovery, in contrast to the irreversibly decreased development in embryos treated with
higher doses (> 50 μg/ml) of the AQ extract. This difference is likely not simply due to
total ginsenoside concentrations, as on a per weight basis ALC > AQ, but due to a varying
compositions of ginsenoside or non-ginsenoside compounds.
In conclusion, the detrimental effect observed on embryonic development induced
by treatment with the AQ and ALC ginseng extracts is concentration dependent, and direct
embryo exposure to ginseng extracts is embryotoxic. Furthermore, once removed from
treatment, embryo recovery is limited for AQ extract treatments greater than 10 μg/ml as
most embryos in AQ treatments did not resume development if arrested at the two-cell and
four-cell stages. In contrast, embryos treated with ALC extracts displayed a greater
recovery from treatment than did the AQ treated embryos. We observed that the ALC
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extract displayed a concentration specific increase in the blockade of development at the
2-cell stage up to 250 μg/ml. This concentration dependent effect however did not occur at
the highest dose used (1000 μg/ml). This outcome is puzzling, but the effect is reminiscent
of high ligand concentration effects on receptor desensitization and thus ligand/receptor
signaling. Our study in no way defines the active component in the extract that is
facilitating this outcome. We simply speculate that the higher dose induced reduction in 2cell developmental blockade allowed greater numbers of embryos to progress to the
blastocyst stage and fully recover from treatment. Clearly there are some important
differences in outcomes observed between direct treatment of early mouse embryos with
AQ and ALC extracts in vitro.
In our study, we used the maximal Rg1 and Rb1 concentrations found in our
extracts, but blastocyst rates were similar for all doses compared to the control. Liu et al.,
2006 found that Rg1 remarkably decreased the total morphological score of postimplantation mouse and rat embryos when concentrations of 30 and 50 μg/ml were tested.
Future studies investigating the effects of Rg1 on early development should consider the
use of higher concentration treatments. Re is the second most prominent ginsenoside found
in NAG extracts and is representative of the PT group. Re exerts a strong postimplantation
embryotoxic effect starting with concentrations of 50 μg/ml (Chan et al., 2004). By
contrast, our experiments displayed no significant delays in preimplantation embryonic
development in vitro between the control and concentrations up to 89.6 μg/ml Re. Thus the
overall conclusion from the single agent and combinatorial treatment experiments or PSF
tested is that none negatively affected mouse preimplantation development. Thus the
impact on preimplantation development observed from AQ and ALC treatment must either
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result from an individual component not yet identified, or the collective effects of several
of the ginseng extract components adversely affecting early embryo development. Our
results are the first to indicate that direct exposure to ginseng extracts is detrimental to
preimplantation development.
These negative in vitro outcomes with whole extracts contrast the findings from in
vivo studies investigating the influence of Red Korean Ginseng treatment two weeks before
mating and throughout gestation on pregnancy in the mouse (Shin et al., 2010). Due to
these discrepancies in outcomes it was essential to conduct in vivo experiments using NAG
on pregnancy and post-partum development in the mouse. In this study doses of 50
mg/kg/day to an extremely high dose of 2000 mg/kg/day NAG (≈ 200 times the
recommended daily dose of 1-2g) were investigated. Even at this dose, we observed no
significant differences in the gestation period, litter size and sex ratio of mice weaned on
post-partum day 20. Females lost weight during the feeding period and gained significantly
less weight during pregnancy, remaining lower through much of lactation, especially in the
aqueous group, which may suggest a toxicity or satiety issue. Ginseng preparations may
decrease post-meal blood glucose (Sievenpiper et al., 2004; Dascalu et al., 2007) or
decrease gut uptake of sugars (Onomura et al., 1999). Most recommended levels for
ginseng product consumption range from 1-2 g per day, indicating that a 50 kg woman
would have to ingest 100 g of ginseng daily to equal the 2000 mg/kg/day level that we
investigated. The 50 mg/kg/day dose is much closer to realistic consumption levels.
We are intrigued by the fact that our in vivo results contrasted dramatically with the
direct effects of NAG on preimplantation embryos. We believe this may be due to the fact
that the concentrations of ginseng directly affecting embryos in vivo are unknown due to
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uncertainties regarding ginseng compound absorption, metabolism and renal clearance rate
after consumption in the human. In light of the high water solubility of ginsenosides, and
their low oral bioavailability, it is very likely that oral consumption results in very little
embryonic exposure to ginseng compounds due to the low trans-placental transfer.
Overall our results support a cautionary approach to determining whether ginseng
extract consumption has a negative influence on pregnancy and post-partum development.
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Figure Descriptions:
Figure 1: Development of 2-cell mouse embryos after 48 h treatment with aqueous
extract. 2-cell embryos were flushed from the oviduct and placed into culture with 01000 μg/ml aqueous extract for 48h (A) and up to 72h recovery (B). Data are presented
as the mean ± SD, representative of three independent replicates. Significant differences
are represented by different superscripts (p≤0.05).

Figure 2: Development of 2-cell mouse embryos after 48 h treatment with alcoholic
extract. 2-cell embryos were flushed from the oviduct and placed into culture with 01000 μg/ml alcoholic extract for 48h (A) and up to 72h recovery (B). Data are presented
as the mean ± SD, representative of three independent replicates. Significant differences
are represented by different superscripts (p≤0.05).

Figure 3: Development and recovery of 2-cell mouse embryos treated with
ginsenoside Rb1. 2-cell embryos were flushed from the oviduct and placed into culture
with 0-164.5 μg/ml Rb1 for 48 h (A) and up to 72h recovery (B). Data are presented as
the mean ± SD, representative of three independent replicates. Significant differences are
represented by different superscripts (p≤0.05).

Figure 4: Development and recovery of mouse embryos following treatment with
ginsenoside Rg1. 2-cell embryos were flushed from the oviduct and placed into culture
with 0-13.1 μg/ml Rb1 for 48 h (A) and up to 72h recovery (B). Data are presented as the
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mean ± SD, representative of three independent replicates. Significant differences are
represented by different superscripts (p≤0.05).

Figure 5: Effect of ginseng treatment (2000 mg/kg/day) on weight during the prebreeding, pregnancy and post-partum periods. Female mice were gavaged with water
(SHAM) or 2000 mg/kg/day of either AQ or ALC ginseng extract for 2 weeks prior to
mating and throughout gestation. Weight gain is reported during pre-breeding (A),
gestation (B) and lactation periods (B). Differences in weight between treatment groups
are presented as the mean ± SD, representative of 5-6 independent replicates. Significant
differences between the SHAM control and ginseng treatments are represented by
different superscripts (p≤0.05).
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